Personalized treatment for rare cancers using tumor markers
Treatments studied
Part of Cancer clinical trials.
This trial tests whether using a precise medicine based on your tumor's unique biomarker can help treat rare cancers more effectively. It aims to offer personalized therapy when standard options are limited.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be able to take care of yourself and be up and about at least half of the day (score 0 to 2 on a standard activity scale).
- Doctors must have identified a specific meaningful change (biomarker) in your tumor that can guide treatment.
- Your blood tests should show that your liver, kidneys, and other organs are working acceptably.
- You should not have any other serious medical conditions that would interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is designed for people with rare types of cancer. It tests new therapies and technologies, and aims to find which ones work best for different tumors. You will need to provide a fresh tumor sample and blood sample for testing.
This study tests targeted drugs or immunotherapy based on the genetic features of your tumor. It may help people with rare, advanced cancers whose disease has progressed after standard treatment options.
This trial tests if growing a patient's tumor cells in the lab (organoids) and analyzing their genes can help doctors choose more effective treatments for rare cancers. You might be eligible if you have an advanced rare solid tumor and can provide fresh or stored tumor tissue for testing.
This trial tests cancer drugs that are already approved for other cancers, chosen based on specific changes found in your tumor. It may help people whose cancer is growing despite standard treatment (or who no longer have standard options).
This Phase 2 trial matches people with advanced cancer to a targeted treatment based on a genetic (DNA) or protein (IHC) test from their tumor. It’s for cancers that are no longer responding to standard treatment or where no standard option is available.
This trial compares treatment based on a detailed analysis of your tumor's genes (genome and transcriptome) with standard care. It aims to find better treatment options for people with advanced rare cancers that have not responded to previous therapy.
Hear when a new Rare Malignant Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.